Definition and epidemiology
Type 2 diabetes mellitus is a chronic disease of impaired glucose homeostasis driven by peripheral insulin resistance combined with inadequate compensatory insulin secretion from pancreatic beta cells. It accounts for roughly 90-95% of all diabetes cases worldwide.
- Global prevalence is estimated at over 500 million adults, with numbers rising sharply due to obesity and aging populations
- Most commonly diagnosed after age 45, but incidence in children, adolescents, and young adults is increasing alongside pediatric obesity
- Higher prevalence in South Asian, Hispanic, African American, and Native American populations
- Strong association with metabolic syndrome: central obesity, hypertension, dyslipidemia
- Metformin is first-line therapy regardless of baseline HbA1c unless contraindicated
- Metformin carries a boxed warning for lactic acidosis, especially with renal impairment or hypoxic states
- Acanthosis nigricans is a clinical clue to underlying insulin resistance
- GLP-1 agonists and SGLT2 inhibitors reduce cardiovascular and renal events independent of glucose lowering
- Diagnosis requires confirmation on a second test unless unequivocal symptomatic hyperglycemia is present
- Unlike type 1 diabetes, DKA is uncommon at baseline but hyperosmolar hyperglycemic state is classic for T2DM
- Diabetic retinopathy is a leading cause of blindness in adults and nephropathy a leading cause of ESRD
- C-peptide and islet autoantibodies help distinguish T2DM from type 1 diabetes/LADA in atypical presentations
- Screening is recommended starting at age 35 for all adults regardless of risk factors
Etiology and risk factors
T2DM results from a combination of genetic predisposition and environmental/lifestyle factors that promote insulin resistance.
- Obesity, particularly visceral/central adiposity, is the strongest modifiable risk factor
- Family history and genetic susceptibility (concordance in monozygotic twins is high)
- Sedentary lifestyle and poor dietary patterns (high refined carbohydrate and saturated fat intake)
- Increasing age
- History of gestational diabetes or polycystic ovary syndrome
- Prediabetes (impaired fasting glucose or impaired glucose tolerance)
- Certain ethnicities (South Asian, Hispanic, African American, Native American, Pacific Islander)
- Medications associated with hyperglycemia: glucocorticoids, atypical antipsychotics, thiazide diuretics
Pathophysiology
Two core defects drive the disease: peripheral insulin resistance and progressive beta-cell failure.
Insulin resistance
Adipose tissue, skeletal muscle, and liver become less responsive to insulin. In the liver this manifests as failure to suppress gluconeogenesis; in muscle and fat, reduced glucose uptake. Excess free fatty acids and adipokines from visceral fat (e.g., reduced adiponectin, increased resistin and inflammatory cytokines) contribute to this resistance.
Beta-cell dysfunction
Initially, beta cells compensate with hyperinsulinemia. Over years, chronic metabolic stress, lipotoxicity, glucotoxicity, and amyloid (amylin) deposition lead to progressive beta-cell exhaustion and apoptosis, resulting in declining insulin secretion.
Net effect
The combination produces fasting and postprandial hyperglycemia. Unlike type 1 diabetes, patients retain some endogenous insulin production, so they are not prone to diabetic ketoacidosis under baseline conditions, though it can occur under severe stress (e.g., infection).
Clinical features
Onset is typically gradual, and many patients are asymptomatic at diagnosis, detected on routine screening.
- Polyuria, polydipsia, polyphagia (less abrupt than in type 1 diabetes)
- Fatigue and blurred vision (due to osmotic changes in the lens)
- Unintentional weight loss (less common than in type 1, occurs with significant hyperglycemia)
- Recurrent infections: candidiasis, urinary tract infections, skin infections
- Acanthosis nigricans (velvety hyperpigmentation at neck/axillae), a marker of insulin resistance
- Peripheral neuropathy symptoms (numbness, tingling) may already be present at diagnosis given the long asymptomatic preclinical phase
- Signs of metabolic syndrome: central obesity, hypertension
Diagnosis
Diagnosis relies on one of several laboratory criteria, generally requiring confirmation with a repeat test on a separate day unless hyperglycemia is unequivocal with classic symptoms.
| Test | Diagnostic threshold |
|---|---|
| Fasting plasma glucose | ≥126 mg/dL (7.0 mmol/L) |
| HbA1c | ≥6.5% |
| 2-hour OGTT (standard oral glucose load) | ≥200 mg/dL (11.1 mmol/L) |
| Random plasma glucose | ≥200 mg/dL with classic symptoms |
- Prediabetes: fasting glucose 100-125 mg/dL, HbA1c 5.7-6.4%, or 2-hour OGTT 140-199 mg/dL
- Screening is recommended for adults with overweight/obesity plus one additional risk factor, or all adults starting at age 35 regardless of risk
- Additional workup after diagnosis: lipid panel, urine albumin-to-creatinine ratio, serum creatinine/eGFR, dilated eye exam, foot exam
- C-peptide and autoantibody testing (anti-GAD, anti-islet cell) are reserved for atypical presentations to distinguish from type 1 diabetes or LADA
Differential diagnosis
- Type 1 diabetes mellitus: typically younger, leaner, prone to ketoacidosis, positive autoantibodies, low C-peptide
- Latent autoimmune diabetes of adults (LADA): adult-onset but autoimmune, slower progression to insulin dependence
- Maturity-onset diabetes of the young (MODY): autosomal dominant, young onset, strong family history, often misdiagnosed as type 2
- Secondary diabetes: due to glucocorticoid excess (Cushing syndrome), acromegaly, pancreatic disease (chronic pancreatitis, cystic fibrosis), or hemochromatosis
- Gestational diabetes: diagnosed during pregnancy, distinct screening criteria
- Drug-induced hyperglycemia: glucocorticoids, antipsychotics, thiazides
Management
Management combines lifestyle intervention with pharmacotherapy, individualized to comorbidities, cardiovascular/renal risk, and patient preference, per ADA/EASD and WHO consensus.
Lifestyle
- Weight loss through dietary modification and structured physical activity (first-line for all patients)
- Medical nutrition therapy, carbohydrate awareness, reduced saturated fat
- Smoking cessation and alcohol moderation
Pharmacotherapy
- Metformin remains first-line unless contraindicated (reduces hepatic gluconeogenesis, improves insulin sensitivity). It carries a boxed warning for lactic acidosis, a rare but potentially fatal risk that increases with renal impairment, heavy alcohol use, hepatic disease, and conditions predisposing to tissue hypoxia; it should be withheld or dose-adjusted accordingly, including temporary discontinuation around procedures using iodinated contrast
- In patients with established atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease, GLP-1 receptor agonists or SGLT2 inhibitors are added or preferred early for their proven cardiorenal benefits, independent of glycemic control
- Additional agents as needed: sulfonylureas, DPP-4 inhibitors, thiazolidinediones, insulin
- Insulin is required when oral/injectable non-insulin agents fail to achieve glycemic targets or in symptomatic severe hyperglycemia
- Individualized HbA1c targets (commonly around 7%, less stringent in elderly or those with limited life expectancy)
Monitoring and prevention of complications
- Regular HbA1c monitoring (every 3-6 months)
- Annual dilated eye exam, foot exam, and urine albumin screening
- Blood pressure and lipid management (statins for cardiovascular risk reduction)
- Vaccinations (influenza, pneumococcal, hepatitis B) as per standard adult immunization guidance
Complications and prognosis
Chronic hyperglycemia causes both microvascular and macrovascular damage, and complications are often present at diagnosis given the long silent prodrome.
Microvascular
- Retinopathy: leading cause of adult blindness; nonproliferative and proliferative stages
- Nephropathy: progressive albuminuria leading to chronic kidney disease; leading cause of end-stage renal disease in many countries
- Neuropathy: distal symmetric sensorimotor polyneuropathy, autonomic neuropathy, risk of diabetic foot ulcers and amputation
Macrovascular
- Accelerated atherosclerosis increasing risk of myocardial infarction, stroke, and peripheral arterial disease (leading cause of death in T2DM)
Acute complications
- Hyperosmolar hyperglycemic state (more characteristic of T2DM than DKA)
- Diabetic ketoacidosis can occur under severe physiologic stress
Prognosis
Early diagnosis and intensive risk-factor control (glycemic, blood pressure, lipid) substantially reduce complication rates. The disease is chronic and progressive; most patients eventually require escalation of therapy, including insulin, over time.
"METFORMIN" first-line: M-etabolic control, E-asy to use, T-olerated well (GI effects), F-irst choice, O-ral agent, R-educes hepatic glucose output, M-inimal hypoglycemia risk, I-nexpensive, N-o weight gain
Practice questions
1. A 52-year-old man with a BMI of 31 presents for a routine checkup. He is asymptomatic. Fasting plasma glucose is 132 mg/dL on two separate occasions. Physical exam reveals velvety hyperpigmentation at the neck. Which of the following is the most appropriate initial pharmacologic therapy?
2. A 61-year-old woman with type 2 diabetes and a history of myocardial infarction two years ago has an HbA1c of 7.8% on metformin monotherapy. Which class of medication should be added to best address both her glycemic control and cardiovascular risk?
3. A 68-year-old man with longstanding type 2 diabetes presents with decreased urine output, confusion, and severe dehydration. Blood glucose is 850 mg/dL. Arterial blood gas shows pH 7.34, and urine ketones are negative. Which condition best explains this presentation?
Frequently asked questions
What causes type 2 diabetes?
Type 2 diabetes is caused by a combination of insulin resistance in muscle, fat, and liver tissue, together with progressive failure of pancreatic beta cells to secrete enough insulin to compensate. Obesity, sedentary lifestyle, genetic predisposition, and aging are the main contributing factors. Unlike type 1 diabetes, it is not primarily an autoimmune process.
What are the first symptoms of type 2 diabetes?
Many people have no symptoms at diagnosis and are identified through routine blood tests. When symptoms occur, they typically include increased thirst, frequent urination, fatigue, blurred vision, and recurrent infections such as yeast infections or urinary tract infections. Symptoms usually develop gradually over months to years, unlike the abrupt onset seen in type 1 diabetes.
How is type 2 diabetes diagnosed?
Diagnosis is based on blood tests: a fasting plasma glucose of 126 mg/dL or higher, an HbA1c of 6.5% or higher, a 2-hour oral glucose tolerance test result of 200 mg/dL or higher, or a random glucose of 200 mg/dL or higher with classic symptoms. Except in cases of unequivocal symptomatic hyperglycemia, results should be confirmed with a repeat test.
Is type 2 diabetes curable?
Type 2 diabetes is not generally considered curable, but it can go into remission with significant weight loss, intensive lifestyle changes, or bariatric surgery in some patients, meaning normal blood glucose without medication. Remission requires sustained effort and is not guaranteed to be permanent, so ongoing monitoring remains important even after glucose levels normalize.
Type 1 vs type 2 diabetes — what is the difference?
Type 1 diabetes is an autoimmune disease causing absolute insulin deficiency, usually presenting in children or young adults who are lean and prone to ketoacidosis. Type 2 diabetes involves insulin resistance plus relative insulin deficiency, typically in older, overweight adults, with a gradual onset and lower risk of ketoacidosis. Autoantibody testing and C-peptide levels help distinguish atypical cases.
Key drugs
Related conditions and differentials
Sources and further reading
StatPearls (NCBI Bookshelf)MedlinePlusWHO ICD-10: E11
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.